Health World Mauritania
SEE OTHER BRANDS

Get your health and wellness news from Mauritania

Health World Mauritania: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health World Mauritania.

Press releases published on September 19, 2025

EIN Presswire Integrates ChatGPT Into Distribution Reports to Track AI Impact on Press Releases
KFSHRC akan Berpartisipasi dalam KTT C3 Davos of Healthcare™ Jepang
キング・ファイサル・スペシャリスト病院・研究センター (KFSHRC)、C3 ダボス・オブ・ヘルスケア™ 日本サミット (C3 Davos of Healthcare™ Japan Summit) に参加
킹파이살 전문병원 겸 연구센터 (KFSHRC), C3 다보스 어브 헬스케어™ 일본 정상회의 참가 예정
KFSHRC akan Menyertai Sidang Kemuncak C3 Davos of Healthcare™ di Jepun
KFSHRC 将参加 C3 Davos of Healthcare™日本峰会
KFSHRC เข้าร่วมการประชุมสุดยอดญี่ปุ่น C3 Davos of Healthcare™
KFSHRC 將參加 C3 Davos of Healthcare™ 日本高峰會
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
AHS leader honored for decades of service in Alameda County
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
North Oaks Unveils $50 Million, 5-Story Specialty Clinic Expansion in Hammond
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions